Ligand Initiates Clinical Trial With The Selective Androgen Receptor Modulator LGD-4033, A Potential Treatment Of Muscle And Bone Disorders
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced the initiation of a Phase I clinical trial with LGD-4033, a next-generation selective androgen receptor modulator (SARM) designed to provide the benefits of androgen receptor stimulation on skeletal muscle and bone without the side effects of currently marketed androgens. The Phase I study will evaluate the safety, tolerability and pharmacokinetic profile of orally administered LGD-4033.
source : www.medicalnewstoday.com
Get 5 Books for 99 cents!
The most popular books at the most popular prices!
Home Income Profit System
You can make money working from the comfort of your own home!
CreditReport.com
Get your credit report and score in just seconds!
Beat your friends on IQ Challenge!
Take the 10-Minute IQ Challenge today. Prove to your friends that you aren't stupid after all!
How DUMB are YOU?!
Do your friends think you are stupid? Take the challenge and prove them wrong!
The most popular books at the most popular prices!
Home Income Profit System
You can make money working from the comfort of your own home!
CreditReport.com
Get your credit report and score in just seconds!
Beat your friends on IQ Challenge!
Take the 10-Minute IQ Challenge today. Prove to your friends that you aren't stupid after all!
How DUMB are YOU?!
Do your friends think you are stupid? Take the challenge and prove them wrong!
Related News:
- European Medicines Agency Makes Recommendations To Minimise Risk Of…
- Breast Enhancement Surgeon on Long Island Nominated a "Best Of"
- $16 Million Grant From State Stem Cell Agency To Speed Research Of…
- Book and Media Reviews: American Psychiatric Publishing Textbook of…
- After Mastectomy: Making a Decision About Breast Reconstruction
- Robotic Surgery Expert Dr. David B. Samadi Discusses The Benefits Of…
- UM Doctor To Lead Clinical Trial For ALS
- Migraine as inspiration
- Impax Pharmaceuticals Reports Positive Results of Phase II Trial of…
- Analysis of TB treatment studies identifies gaps in guidelines
Details :
Submited at Friday, June 19th, 2009 at 8:01 am on Orthopaedic by madison
Comment RSS 2.0 - leave a comment - trackback
Leave Comment Here...
















